EHA 2026: Low-Dose Venetoclax Demonstrates Durable Responses in Relapsed/Refractory t(11;14) Multiple Myeloma

Phase 2 data from the VICTORIA study show that low-dose venetoclax achieved responses in 60% of patients with relapsed/refractory t(11;14) multiple myeloma, with those responding demonstrating long and durable responses and many achieving complete or stringent complete response. In this EHA 2026 update, Astrid Hundebøll Torpe, MD, PhD fellow, Copenhagen University Hospital, discusses the findings and ongoing translational analyses.